ParaZero Secures New European Order for SafeAir M4 Systems, Expanding Presence in Innovative Drone Market
TEL AVIV, Israel, May 13, 2025 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (the 'company' or 'ParaZero'), an aerospace company focused on safety systems for commercial unmanned aircrafts and defense counter-UAS systems, today announced a follow-on purchase order for its innovative SafeAir™ M4 parachute recovery system from a prominent drone technology partner in Europe. This order reflects ParaZero's growing traction in Europe's dynamic drone market, a hub for advanced unmanned aerial systems (UAS) in logistics, infrastructure inspection, and public safety.
The SafeAir™ M4, ParaZero's next-generation autonomous parachute recovery system, is designed for seamless integration with DJI's Matrice 4 series. It features real-time telemetry and is designed and expected to comply with the highest European regulatory standards to enable safe flight in urban areas throughout the EU.
The European partner, a key player in the region's commercial drone ecosystem, serves enterprise clients in precision agriculture, infrastructure inspection, and emergency response. This order reflects increasing demand for ParaZero's certified safety solutions in high-regulation markets, following the Company's recent CE Class C5 certification and other regulatory approvals for its SafeAir™ systems.
'This order from our European partner highlights the SafeAir™ M4's role in enabling safe, scalable drone operations in one of Europe's most innovative UAS markets,' said Boaz Shetzer, CEO of ParaZero. 'We are proud of our collaborate with a leading partner, who has already placed orders in the past, and this follow-up order is a testament to the strong value we bring to European operators, supporting their ambitions in unmaned aerial systems and beyond.'
About ParaZero Technologies
ParaZero (Nasdaq: PRZO) is a leading developer of autonomous parachute safety systems technologies for commercial and military platforms as well as for urban air mobility (UAM) aircraft. Started in 2014 by a passionate group of aviation professionals and drone industry veterans, ParaZero develops and manufactures smart, autonomous parachute safety systems designed to enable safe flight operations over populated areas and beyond-visual-line-of-sight (BVLOS) as well as for various military applications including Counter UAS. For more information about ParaZero, please visit https://parazero.com/
Forward-Looking Statements
This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates' and similar expressions or variations of such words are intended to identify forward-looking statements. For example, ParaZero is using forward-looking statements when it discusses how the SafeAir™ M4 is expected to comply with the highest European regulatory standards to enable safe flight in urban areas throughout the EU, the increasing demand for ParaZero's certified safety solutions in high-regulation markets and the the strong value that ParaZero bring to European operators. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ('SEC'), including, but not limited to, the risks detailed in the Company's Annual Report on Form 20-F filed with the SEC on March 21, 2024. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. ParaZero is not responsible for the content of third-party websites.
Investor Relations Contact:
Michal EfratyInvestor Relations
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
22 minutes ago
- Business Wire
Mursla Bio Introduces AI Precision Medicine Platform Built on Organ-Specific EV Isolation from Blood
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to advance precision diagnostics and significantly improve cancer outcomes for at-risk patients, today announced the commercial launch of its AI Precision Medicine Platform, alongside a pre-print¹ reporting the first validated method for isolating hepatocyte EVs from plasma for organ-specific proteomic and miRNA profiling. Mursla Bio is engaging with potential partners to apply its Platform to additional disease areas, biomarker discovery and IVD translation programs. The Platform addresses a major gap in liquid biopsy and precision medicine: enabling non-invasive access to organ-specific molecular information from blood with high spatial and biological resolution. Mursla Bio's Platform is built on its ability to isolate and analyze EVs which are secreted by specific organs into the bloodstream. The Platform reduces non-target background by up to five orders of magnitude compared to standard bulk EV isolation and significantly improves data structure, enhancing prediction model generalization. The pre-print presents the first multi-layered validation of hepatocyte EV isolation in humans, confirming liver origin through proteomic and nucleic acid markers. Key supporting proteomics data was generated in collaboration with Evotec International GmbH. Patient samples were provided by University College London, with Professor Brian Davidson, a global leader in liver disease surgery and clinical research, contributing as a co-author. The study shows that Mursla Bio's method yields robust, organ-specific multi-omics data using minimal blood volume, offering a novel scalable approach for biomarker and AI development. Mursla Bio's Platform incorporates optimized multi-omics workflows, embedded AI pipelines, and IVD translation processes to convert complex biological signals into practical, regulatory-grade assays. These assays are deployable on standard commercial instruments using patented, PCR and ELISA-like steps designed for clinical adoption. The Platform also underpins the development of EvoLiver™, the Company's lead clinical program for liver cancer surveillance in cirrhotic patients. Built on multi-omics data from over 300 patients, EvoLiver achieved 86% sensitivity and 88% specificity on a locked, IVD-compatible assay for early-stage hepatocellular carcinoma detection², and has received Breakthrough Device Designation from the FDA³. Pierre Arsène, Founder and CEO of Mursla Bio, said: "EVs are nature's native signal enrichment system for long-distance communication between cells and organs. Our platform harnesses this biology to non-invasively access organ-specific, multi-omics data from just a small blood sample. It produces structured, biologically labeled datasets that are optimized for AI and ready to support diagnostic translation. EvoLiver is our first proof point of real-world clinical impact, and we are now expanding access to the platform to advance our pipeline and enable partnerships across other disease areas.' Mursla Bio is expanding its pipeline and collaborations, with additional organ programs underway in cardiometabolic, lung, and neurological indications. The Platform will support pharma development through dynamic patient stratification, therapeutic response monitoring, surrogate markers and molecular phenotyping across complex disease biology. For further information on Mursla Bio's AI Precision Medicine Platform, please visit
Yahoo
an hour ago
- Yahoo
Mizuho remains bullish on data centers; DLR remains top pick
-- Analysts at Mizuho Securities remain bullish on data center REITs, reaffirming Digital Realty Trust (NYSE:DLR) as their top pick while raising price targets following first-quarter earnings updates. Despite recent outperformance, the analysts note that the sector continues to capitalize on strong bookings and ongoing demand from hyperscale customers. Digital Realty shares now trade at 27 times adjusted funds from operations (AFFO), representing a 30% premium to the broader REIT group. While some bears may argue 'good news' is already priced in, Mizuho's team sees multiple catalysts ahead. The firm lifted its price target on the stock to $191 from $177, applying a 27x AFFO multiple to its estimates for fiscal year 2026 (FY26). New FFO forecasts stand at $7.13 for 2025 and $7.63 for 2026, with estimates modestly above consensus for 2025. For Equinix (NASDAQ:EQIX), another key player in the data center space, Mizuho raised its price target to $1,069 from $1,053, reflecting updated FFO estimates of $38.08 and $41.12 for 2025 and 2026, respectively. Mizuho's outlook for Digital Realty incorporates several key drivers. The analysts model strong rent spreads of 6% and 7% in 2025 and 2026, alongside occupancy gains of 170 and 200 basis points, respectively. They also point to upside potential in the company's 0-1MW segment, noting management conversations that suggest a path to doubling revenue in that category by mid-to-late FY26. 'On average, the company has booked about $50mm in revenue in the last two years and a broad goal is to get to a quarterly run-rate of $100mm,' the analysts said. 'Our conversations with management suggest there is a path to that level during the next 2-3 years.' 'Theoretically, at a 50% margin, a $400mm run-rate, this could add 1-2% growth to the bottom line,' they added. Mizuho views the recently formed investment fund as a significant growth lever. The analysts believe the fund 'could become much larger than the current estimate of $10bn to potentially match or exceed other large REIT funds.' They see benefits over traditional joint ventures, including 'a more favorable fee structure and greater control over the assets/transactions and mitigating the risk of scaling the development pipeline.' Mizuho also expects the fund structure to enable Digital Realty to recycle stabilized assets into the fund at attractive cap rates while allocating capital toward higher-growth projects. Depending on when the fund closes, likely by year-end 2025, overall FFO could increase by 3 to 5 cents, according to the note. On valuation, despite higher multiples relative to historical levels, Mizuho argues the stock premium is justified given strong bookings and the additional upside potential from the fund. Related articles Mizuho remains bullish on data centers; DLR remains top pick Analysts start with bullish ratings on Hinge Health on growth potential UBS starts coverage on packaged food stocks with cautious tone, Sell on Freshpet
Business Wire
an hour ago
- Business Wire
Europe´s Auto Industry Installed 23,000 New Robots
FRANKFURT AM MAIN, Germany--(BUSINESS WIRE)-- Investment in automating the car industry in Europe remains high. The total number of industrial robots installed reached 23,000 in 2024, which is the second-best result in five years. These are preliminary results presented by the International Federation of Robotics (IFR). Europe´s Auto Industry Installed 23,000 New Robots Share "The European automotive sector is the region's strongest customer industry for robotics," says Takayuki Ito, President of the International Federation of Robotics. 'Car makers are accounting for around a third of annual manufacturing installations in Europe. In terms of automation activity, the combined number of 23,000 European robot installations in the car sector was ahead of the 19,200 units installed in North America in 2024.' Automotive robot density At a global level, Europe´s car manufacturing is highly automated: Six European countries are among the top ten in the world's robot density ranking for the automotive industry in 2023: Switzerland is in first place, with a ratio of 3,876 robots to 10,000 factory workers. Slovenia is in third place (1,762 units), Germany in sixth (1,492 units), Austria in eighth (1,412 units), Finland in ninth (1,288 units), and the Benelux countries are in tenth place with 1,132 units. European Union is in lead Apart from Switzerland, all of these automation champions are EU member states. The EU27 countries' leading role is evident not only in the automotive industry, but across all sectors, accounting for around 85% of all regional installations in 2024. Germany, which belongs to the five major robot markets in the world, had a share of about 30% of the total installations in Europe. Italy followed with about 10% and Spain with about 6%. From 2019 to 2024, the compound annual growth rate (CAGR) of robots installed in the Europe was +3%. IFR Executive Round Table, June 25 in Munich Downloads Press releases, graphics, photos About IFR The International Federation of Robotics is the voice of the global robotics industry: The IFR Statistical Department provides data for two annual robotics studies: Follow IFR on LinkedIn and YouTube
